According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are $2.34 Billion USD. In 2024 the company made an earning of -$0.24 Billion USD, an increase over its 2023 earnings that were of -$0.32 Billion USD. The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2025 (TTM) | -$0.22 Billion | -10.78% |
2024 | -$0.24 Billion | -24.59% |
2023 | -$0.32 Billion | -67.84% |
2022 | -$0.98 Billion | 36.93% |
2021 | -$0.71 Billion | -8.04% |
2020 | -$0.78 Billion | -15.66% |
2019 | -$0.92 Billion | 12.23% |
2018 | -$0.82 Billion | 62.91% |
2017 | -$0.51 Billion | 17.78% |
2016 | -$0.43 Billion | 43.44% |
2015 | -$0.3 Billion | 60.69% |
2014 | -$0.19 Billion | 98.2% |
2013 | -$92.95 Million | |
2011 | -$54.82 Million | 27.48% |
2010 | -$43.01 Million | -10.92% |
2009 | -$48.28 Million | 95.77% |
2008 | -$24.66 Million | |
2006 | -$39.51 Million | -9.13% |
2005 | -$43.48 Million | 34.74% |
2004 | -$32.27 Million | 36.79% |
2003 | -$23.59 Million |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
![]() Arrowhead Pharmaceuticals
ARWR | -$89.25 Million | -57.53% | ๐บ๐ธ USA |
![]() Regeneron Pharmaceuticals REGN | $4.98 B | -2,471.93% | ๐บ๐ธ USA |
![]() Sarepta Therapeutics
SRPT | -$0.17 Billion | -21.86% | ๐บ๐ธ USA |
![]() OPKO Health
OPK | -$0.56 Million | -99.74% | ๐บ๐ธ USA |
![]() Regulus Therapeutics RGLS | -$47.43 Million | -77.43% | ๐บ๐ธ USA |
![]() Novartis NVS | $14.91 B | -7,199.31% | ๐จ๐ญ Switzerland |
![]() Sanofi SNY | $8.76 B | -4,273.11% | ๐ซ๐ท France |
![]() Teva Pharmaceutical Industries TEVA | $0.45 B | -316.05% | ๐ฎ๐ฑ Israel |